{"text": "Secondary analysis of a randomized clinical trial that included 312 participants with macular edema secondary to CRVO or hemiretinal vein occlusion (HRVO) who were not taking IOP-lowering medications at baseline.\nFirst randomization occurred on September 14, 2014, and contained data through data freeze on April 1, 2020.\nAnalysis took place from April 2020 through December 2020.\nStudy participants were initially randomized to 6 monthly intravitreal injections of aflibercept or bevacizumab.\nAt month 6, protocol-defined good responders were rerandomized to continued monthly or treat-and-extend dosing of their originally assigned study drug, and protocol-defined poor or marginal responders were switched to alternative treatment.\nAfter month 12, participants were treated as per investigator discretion.\nThree different outcomes: (1) IOP elevation more than 10 mm Hg from baseline, (2) IOP to a level higher than 35 mm Hg, and (3) IOP-lowering incisional or laser surgery.", "label": []}
{"text": "Randomized, prospective and multicentre clinical trial.\nSettings: Six clinical centres.\nPatients 54-89\u00a0years of age without previous filtering surgery with cataract and glaucoma who required lower levels of intraocular pressure (IOP).\nPhaco-EX-PRESS P50 or Phaco-NPDS with Esnoper V2000, both groups with mitomycin C (0.2\u00a0mg/ml for 2\u00a0min).\nIOP, complete success rate (IOP: \u22656 and \u226418\u00a0mmHg), visual acuity, use of medical therapy and systematic assessment of complications and postoperative interventions.", "label": []}
{"text": "The SCORE2 randomized noninferiority clinical trial was conducted at 66 private practice or academic centers in the United States, and included 362 patients with macular edema due to central retinal or hemiretinal vein occlusion who were randomized 1:1 to receive aflibercept or bevacizumab.\nThe first participant was randomized on September 17, 2014, and the last month 6 visit occurred on May 6, 2016.\nAnalyses included data available as of December 30, 2016.\nEyes were randomized to receive intravitreal injection of bevacizumab (1.25 mg; n\u2009=\u2009182) or aflibercept (2.0 mg; n\u2009=\u2009180) every 4 weeks through month 6.\nThe primary outcome was mean change in visual acuity (VA) letter score (VALS) from the randomization visit to the 6-month follow-up visit, based on the best-corrected electronic Early Treatment Diabetic Retinopathy Study VALS (scores range from 0-100; higher scores indicate better VA).\nThe noninferiority margin was 5 letters, and statistical testing for noninferiority was based on a 1-sided 97.5% confidence interval.", "label": []}
{"text": "Multicenter randomized clinical trial.\nSetting: Seventeen clinical centers.\nPatients 18-85 years of age with medically uncontrolled glaucoma who had previous cataract and/or glaucoma surgery.\nTube shunt (350-mm\nVision-specific QoL using the NEI VFQ-25 and estimation of minimally important differences (MID) were the main outcome measures.\nCross-sectional distribution- and anchor-based approaches were used to estimate MID.\nClinical anchor measures included the mean deviation (MD) and logMAR visual acuity (VA) measurements.\nClinically significant changes in anchor were defined as \u22652 dB MD and \u22650.2 logMAR.", "label": []}
{"text": "Randomized, controlled, observer-masked clinical trial.\nsetting: Two US clinical sites.\nEligible patients were adults diagnosed with open-angle glaucoma or ocular hypertension.\nPatients (n\u00a0= 81) were sequentially randomized 1:1 to receive TTFC or TRAV+TIM for 12\u00a0months.\nTTFC was administered once daily in the morning or evening with a single dosing aid.\nPatients randomized to TRAV+TIM administered TRAV once daily in the evening and TIM once daily in the morning using separate dosing aids.\nAdherence with administered medication, as recorded by the dosing aids.", "label": []}
{"text": "Interventional case series, prospective, randomized, masked, controlled clinical trial.\nSetting: Meir Medical Center, Kfar-Saba, Israel.\nAdults with uncontrolled primary open angle or pseudoexfoliation glaucoma randomized into 2 groups.\nThe controls underwent conventional SLT with 100 spots delivered using a gonioscopy lens for 360 degrees of the trabecular meshwork.\nThe study group underwent irradiation using the same parameters with the laser applications administered on the perilimbal sclera.\nStudy visits: 1 hour, 1, 7, 30, 60, 180, and 365 days postprocedure.\nIntraocular pressure (IOP) and side effects.", "label": []}
{"text": "Multicenter, randomized, evaluator-masked (Study 1)/double-masked (Study 2), parallel-group studies.\nSetting: Twenty-eight clinical sites (Study 1) and 19 clinical sites (Study 2) in Japan.\nOutpatients with bilateral POAG or OH whose predose IOP was 18 to <35\u00a0mm Hg in the study eye after 4\u00a0weeks' treatment with latanoprost (Study 1) or carteolol (Study 2) (defined as baseline).\nIn Study 1, 237 patients applied OPC-1085EL (n\u00a0= 118) or latanoprost (n\u00a0= 119) for 8 weeks.\nIn Study 2, 193 patients applied OPC-1085EL (n\u00a0= 78), carteolol (n\u00a0= 78), or carteolol/latanoprost concomitant therapy (n\u00a0= 37) for 8\u00a0weeks.\nAdjusted mean IOP reduction at predose from baseline to week 8.", "label": []}
{"text": "This randomized clinical trial studied 222 consecutive patients undergoing trabeculectomy from October 1, 2014, through November 31, 2015, at 4 rural hospitals in Guangdong and Guangxi Provinces, China.\nData from the intention-to-treat population were analyzed.\nPatients undergoing trabeculectomy were randomized (1:1) to receive text message reminders 3 days before appointments at 1 and 2 weeks and 1 month after surgery and free topical corticosteroid medication (US$5.30) at each visit or to standard follow-up without reminders or free medication.\nFollow-up at 1 month postoperatively.", "label": []}
{"text": "Multicenter, randomized, double-masked, parallel-group phase 4 clinical trial.\nsetting: Multicenter; 32 sites in the United States.\nTotal of 233 patients with open-angle glaucoma or ocular hypertension and with mean intraocular pressure (IOP) \u226521\u00a0mm Hg and <32\u00a0mm Hg while receiving once-daily TRAV monotherapy.\nMasked BBFC or vehicle (3 times daily) adjunctive to TRAV for 6\u00a0weeks.\nMean diurnal IOP averaged over 8 AM, 10 AM, 3 PM, and 5 PM time points at week 6.\nSuperiority of BBFC+TRAV over vehicle+TRAV was based on statistical significance of a treatment difference favoring BBFC+TRAV.", "label": []}
{"text": "Multicenter, prospective randomized clinical trial.\nsetting: Sixteen international clinical centers.\nTwo hundred seventy-six subjects aged 18-85 years with previous intraocular surgery or refractory glaucoma with intraocular pressure of >18 mm Hg.\nAhmed Glaucoma Valve FP7 or Baerveldt Glaucoma Implant BG 101-350.\nLate postoperative complications (beyond 3 months), reoperations for complications, and decreased vision from complications.", "label": []}
{"text": "A multicenter randomized clinical trial of 114 infants with unilateral congenital cataract in referral centers who were between ages 1 and 6 months at surgery.\nMean follow-up was 4.8 years.\nThis secondary analysis was conducted from December 23, 2004, to November 13, 2013.\nParticipants were randomized at cataract surgery to either primary IOL or no IOL implantation (contact lens).\nStandardized definitions of glaucoma and glaucoma suspect were created for the Infant Aphakia Treatment Study and applied for surveillance and diagnosis.\nDevelopment of glaucoma and glaucoma\u2009+\u2009glaucoma suspect in operated on eyes for children up to age 5 years, plus intraocular pressure, visual acuity, and axial length at age 5 years.", "label": []}
{"text": "Prospective double-masked randomized crossover study.\nsetting: Clinical practice.\nOne eye per patient with primary open-angle glaucoma and stable intraocular pressure (IOP).\nPatients were randomized to receive 1 acupuncture series (12 sessions with either eye-related [eye-points] or non-eye-related [non-eye-points] acupoints) and then crossed over to receive the other series.\nIOP, blood pressure (BP), heart rate (HR), best-corrected visual acuity (BCVA), visual field (VF), optic disc and peripapillary retinal nerve fiber layer (RNFL) measurements, compliance, and adverse reactions.\nProbability to detect 3 mm Hg IOP difference between series was 90%.", "label": []}
{"text": "Double-masked, randomized, 2-treatment, equivalence clinical trial.\nsetting: Multicenter clinical trial conducted in 60 centers in the United States and Europe.\nAdult patients with open-angle glaucoma or ocular hypertension.\nOne eye per patient was analyzed.\nPatients were randomized 1:1 to receive polyquaternium-1-preserved travoprost 0.003% (n = 442) or benzalkonium chloride-preserved travoprost 0.004% (n = 422) once daily for 3 months.\nMean intraocular pressure (IOP) was assessed at 8 AM, 10 AM, and 4 PM at week 2, week 6, and month 3.\nSupportive outcomes were mean and percent IOP change, percentage of patients achieving IOP <18 mm Hg or \u226530% IOP reduction, and adverse events.", "label": []}
{"text": "We conducted 2, multicenter, randomized, double-masked, parallel group comparison studies of ripasudil-timolol and ripasudil-latanoprost in 29 and 36 Japanese clinical centers, respectively.\nAnalyses were performed on an intention-treat-treat basis.\nAfter appropriate run-in periods with timolol or latanoprost, 208 and 205 patients whose IOP levels were 18 mm Hg or higher were enrolled in the ripasudil-timolol and ripasudil-latanoprost groups, respectively.\nEnrollment began December 1, 2011, and follow-up was completed on September 7, 2012, in the ripasudil-timolol study.\nEnrollment began December 1, 2011, and follow-up was completed on September 27, 2012, in the ripasudil-latanoprost study.\nPatients were subdivided into 2 groups in each study and were treated with ripasudil or placebo twice daily for 8 weeks.\nThe IOP reductions in the ripasudil and placebo groups were analyzed with a repeated-measures analysis of variance model at weeks 4, 6, and 8, at trough (before instillation [9 am]) and peak (2 hours after instillation [11 am]) levels.", "label": []}
{"text": "Randomized clinical trial at tertiary eye care institutions of 100 patients diagnosed as having PAC or PAC glaucoma in which the angles had opened at least 180\u00b0 (visible posterior trabecular meshwork on gonioscopy) after laser iridotomy.\nRecruitment and baseline\u00a0were completed from June 2009 to April 2012 and 6-month follow-up was completed from December 2009 to November 2012.\nEligible patients with a baseline IOP greater than 21 mm Hg were randomized to either SLT or prostaglandin analog (PGA; travoprost, 0.004%).\nThe SLT was repeated if the IOP reduction was less than 20.0% from baseline at the 1- or 3-month follow-up visit.\nThe primary outcome measure was the change in IOP from baseline to the final follow-up visit (at 6 months).\nThe frequency of additional postoperative treatments and complications were secondary outcomes.", "label": []}
{"text": "Multicenter prospective, double-masked, controlled clinical trial conducted at 80 clinical sites.\nOne hundred five surgeons enrolled 1090 participants undergoing corneal transplant for a moderate-risk condition, principally Fuchs dystrophy or pseudophakic or aphakic corneal edema (PACE).\nForty-three eye banks provided corneas.\nCorneas from donors younger than 66 years and donors 66 years or older were assigned, masked to donor age.\nSurgery and postoperative care were performed according to the surgeons' usual routines.\nParticipants were followed up for as long as 12 years.\nGraft failure, defined as a regrafting procedure or a cloudy cornea for 3 consecutive months.", "label": []}
{"text": "Six-month, phase 3, randomized, multicenter, double-masked clinical trial.\nA total of 560 patients with primary open-angle glaucoma or ocular hypertension who had insufficient IOP reduction with their current therapeutic regimen or who were receiving \u2265 2 IOP-lowering medications.\nPatients received BBFC (n = 193), brinzolamide 1% (n = 192), or brimonidine 0.2% (n = 175) BID.\nThe primary end point was mean change in diurnal IOP from baseline to month 3.\nSupportive end points included mean diurnal IOP change from baseline at week 2, week 6, and month 6; and mean IOP, mean IOP change from baseline, mean percentage IOP change from baseline, and percentage of patients with IOP <18 mmHg at week 2, week 6, month 3, and month 6 at each assessment time point (i.e., 9 am, 11 am, and 4 pm).\nAdverse events were recorded throughout the study.", "label": []}
{"text": "A prospective, multicenter, interventional cohort from the prerandomization phase of a randomized clinical trial evaluating use of a supraciliary implant for treatment of IOP was conducted at multiple ophthalmology clinics.\nA total of 609 patients (609 eyes) with primary open-angle glaucoma and cataract were included.\nOne IOP measurement was made while patients were receiving their usual medications to lower IOP, and 3 IOP measurements were made at 8 am, 12 pm, and 4 pm after patients underwent washout of all IOP-lowering eyedrops.\nThe proportion of eyes in which the increase in IOP after washout, using the mean of the 3 measurements, differed by more than 0.5, 1.0, 1.5, or 2.0 mm Hg from the increase in IOP after washout using only 1 of the postwashout measurements.\nA proportion of 10% or less at the 1.5-mm Hg cutoff was considered clinically acceptable.\nThe hypothesis was formulated after data collection but before the data were examined.", "label": []}
{"text": "We performed a prospective cohort study of medication adherence, followed by a randomized intervention for those found to be nonadherent, of individuals recruited from a university-based glaucoma subspecialty clinic.\nA total of 491 participants were enrolled in the initial assessment of adherence.\nOf those, 70 were nonadherent with their medications after 3 months of electronic monitoring and randomized to intervention and control groups.\nA personal health record was used to store the list of patient medications and reminder preferences.\nOn the basis of those data, participants randomized to the intervention received daily messages, either text or voice, reminding them to take their medication.\nParticipants randomized to the control group received usual care.\nDifference in adherence before and after initiation of the intervention.", "label": []}
{"text": "Prospective randomized clinical trial.\nInstitutional-Wills Eye Hospital.\nPatients undergoing trabeculectomy (with or without cataract surgery) or tube shunt surgery.\nPatients were randomized to receive intracameral TA or balanced salt solution at the end of surgery.\nFollow-up time was 6 months.\nIntraocular pressure, visual acuity, inflammation measured by slit-lamp examination and laser flare meter, cataract grading, bleb appearance, dry eye scores, use of supplemental medical therapy, surgical success, and rate of complications.", "label": []}
{"text": "The Infant Aphakia Treatment Study is a randomized clinical trial with 5 years of follow-up that involved 114 infants with unilateral congenital cataracts at 12 sites.\nA traveling examiner assessed visual acuity at age 4.5 years.\nCataract surgery with or without primary IOL implantation.\nContact lenses were used to correct aphakia in patients who did not receive IOLs.\nTreatment was determined through random assignment.\nHOTV optotype visual acuity at 4.5 years of age.", "label": []}
{"text": "Double-blind, randomized, crossover study.\nNondiabetic pseudophakic patients with definite POAG were recruited; 29 eyes of 16 individuals participated in study 1.\nA follow-up study (study 2) included 14 eyes of 7 individuals.\nEyes were randomly allocated to receive 50% glucose or saline eye drops every 5 minutes for 60 minutes.\nThe contrast sensitivity and best-corrected logarithm of the minimum angle of resolution (logMAR).", "label": []}
{"text": "A total of 27,347 postmenopausal women aged 50 to 79 years were enrolled at 40 US centers.\nWomen with an intact uterus received conjugated equine estrogens (CEE; 0.625 mg/d) plus medroxyprogesterone acetate (MPA; 2.5 mg/d) (n\u2009=\u20098506) or placebo (n\u2009=\u20098102).\nWomen with prior hysterectomy received CEE alone (0.625 mg/d) (n\u2009=\u20095310) or placebo (n\u2009=\u20095429).\nThe intervention lasted a median of 5.6 years in CEE plus MPA trial and 7.2 years in CEE alone trial with 13 years of cumulative follow-up until September 30, 2010.\nPrimary efficacy and safety outcomes were coronary heart disease (CHD) and invasive breast cancer, respectively.\nA global index also included stroke, pulmonary embolism, colorectal cancer, endometrial cancer, hip fracture, and death.", "label": []}
{"text": "Exploratory analysis was performed on worsening of retinopathy, defined as 1 or more of the following: (1) worsening from no PDR to PDR, (2) worsening of 2 or more severity levels on reading center assessment of fundus photographs in eyes without PDR at baseline, (3) having panretinal photocoagulation, (4) experiencing vitreous hemorrhage, or (5) undergoing vitrectomy for the treatment of PDR.\nCommunity- and university-based ophthalmology practices.\nIndividuals with central-involved diabetic macular edema causing visual acuity impairment.\nEyes were assigned randomly to sham with prompt focal/grid laser, 0.5 mg of intravitreal ranibizumab with prompt or deferred (\u226524 weeks) laser, or 4 mg of intravitreal triamcinolone acetonide with prompt laser.\nThree-year cumulative probabilities for retinopathy worsening.", "label": []}
{"text": "In this phase 3, double-masked, parallel-group, multicenter study, eligible patients were randomized 1:1:1 to treatment with fixed-combination brinzolamide, 1%, and brimonidine, 0.2%; brinzolamide, 1%; or brimonidine, 0.2%, 3 times daily for 3 months.\nSixty-six academic and private practice study sites throughout the United States.\nA total of 660 adults with a clinical diagnosis of open-angle glaucoma or ocular hypertension from a referred sample were enrolled.\nThirty-four patients discontinued participation due to treatment-related nonserious adverse events.\nTopical administration of study medication (fixed-combination brinzolamide, 1%, and brimonidine, 0.2%; brinzolamide, 1%; or brimonidine, 0.2%) 1 drop 3 times daily for 3 months.\nMean IOP at the 3-month visit at all time points (8 AM, 10 AM, 3 PM, and 5 PM).", "label": []}
{"text": "Prospective, randomized clinical trial.\nFifty medically uncontrolled CACG eyes without cataract of 50 patients.\nPatients were randomized into undergoing either phacoemulsification or trabeculectomy with adjunctive mitomycin C. After surgery, patients were followed up every 3 months for 2 years.\nIntraocular pressure (IOP) and requirement for glaucoma drugs.", "label": []}
{"text": "Multicenter randomized clinical trial.\nSeventeen clinical centers.\nPatients 18 to 85 years of age who had previous trabeculectomy and/or cataract extraction with intraocular lens implantation and uncontrolled glaucoma with intraocular pressure (IOP) \u226518 mm Hg and \u226440 mm Hg on maximum tolerated medical therapy.\nTube shunt (350-mm(2) Baerveldt glaucoma implant) or trabeculectomy with mitomycin C ([MMC]; 0.4 mg/mL for 4 minutes).\nIOP, visual acuity, use of supplemental medical therapy, and failure (IOP >21 mm Hg or not reduced by 20%, IOP \u22645 mm Hg, reoperation for glaucoma, or loss of light perception vision).", "label": []}
{"text": "Multicenter randomized clinical trial.\nSeventeen clinical centers.\nPatients 18 to 85 years of age who had previous trabeculectomy and/or cataract extraction with intraocular lens implantation and uncontrolled glaucoma with intraocular pressure (IOP) \u226518 mm Hg and \u226440 mm Hg on maximum tolerated medical therapy.\nTube shunt (350-mm(2) Baerveldt glaucoma implant) or trabeculectomy with mitomycin C (MMC 0.4 mg/mL for 4 minutes).\nSurgical complications, reoperations for complications, visual acuity, and cataract progression.", "label": []}
{"text": "Observational cohort study.\nFour hundred one infants in whom high-risk prethreshold ROP developed in 1 or both eyes and were randomized to early treatment (ET) versus conventional management (CM).\nRefractive error was measured by cycloplegic retinoscopy.\nEyes were excluded if they underwent additional retinal, glaucoma, or cataract surgery.\nEyes were randomized to receive laser photocoagulation at high-risk prethreshold ROP or to receive treatment only if threshold ROP developed.\nAstigmatism and high astigmatism at each study visit.", "label": []}
{"text": "Phase 1, open-label, multicenter study.\nPediatric patients of 3 age groups (<3, 3-<12, and 12-<18 years) and adults (\u226518 years) receiving latanoprost ophthalmic solution 0.005% once daily in 1 or both eyes for \u22652 weeks.\nLatanoprost was administered in both eyes each morning post-screening.\nSubjects returned 3 to 28 days later for evaluation of plasma concentrations, withholding morning latanoprost.\nAt the clinic, a single drop of latanoprost ophthalmic solution was instilled into both eyes.\nPlasma latanoprost acid concentrations were collected predose and 5, 15, 30, and 60 minutes after administration.\nLatanoprost acid plasma exposure.", "label": []}
{"text": "This was a randomised controlled study in a tertiary care centre in which 60 adults scheduled for elective non-ophthalmic procedures under general anaesthesia were allocated to one of three groups.\nPatients with pre-existing glaucoma, cardiovascular, pulmonary or metabolic diseases or anticipated difficult intubation were excluded.\nFollowing induction of general anaesthesia, an endotracheal tube, LMA or i-gel device was inserted.\nIOP, SBP, DBP, heart rate (HR) and perfusion index were measured before induction of anaesthesia and before and after insertion of the airway device.", "label": []}
{"text": "Two multicenter, randomized clinical trials, 1 evaluating participants with central retinal vein occlusion (CRVO) and the other evaluating participants with branch retinal vein occlusion (BRVO).\nAt 36 months, data were available for 81 participants with CRVO and 128 with BRVO.\nStandard care (observation or grid photocoagulation) versus 1 or 4 mg intravitreal triamcinolone.\nNeovascularization of the iris (NVI), neovascular glaucoma (NVG), disc or retinal neovascularization (NVD/NVE), preretinal or vitreous hemorrhage (PRH/VH), and nonperfusion.", "label": []}
{"text": "Prospective, randomized, controlled 3-year trial.\nOne hundred sixteen eyes of 116 patients with PDS and OHT.\nPatients were assigned randomly either to Nd:YAG LPI or to a control group (no laser).\nThe primary outcome measure was conversion to PG within 3 years, based on full-threshold visual field (VF) analysis using the Ocular Hypertension Treatment Study criteria.\nSecondary outcome measures were whether eyes required topical antiglaucoma medications during the study period and the time to conversion or medication.", "label": []}
{"text": "Prospective, randomized, open-label, controlled, multicenter clinical trial.\nA total of 240 eyes with mild to moderate open-angle glaucoma with intraocular pressure (IOP) \u226424 mmHg controlled on 1 to 3 medications were randomized to undergo cataract surgery with iStent implantation (treatment group) or cataract surgery only (control).\nFifty additional subjects were enrolled to undergo cataract surgery with iStent implantation under protocol expansion.\nData in this report are based on the first 240 eyes enrolled.\nImplantation of the iStent trabecular micro-bypass stent in conjunction with cataract surgery or cataract surgery only.\nThe primary efficacy measure was unmedicated IOP \u226421 mmHg at 1 year.\nA secondary measure was unmedicated IOP reduction \u226520% at 1 year.\nSafety measures included best-corrected visual acuity (BCVA), slit-lamp observations, complications, and adverse events.", "label": []}
{"text": "Multicenter randomized clinical trial.\nSeventeen clinical centers.\nPatients 18 to 85 years of age who had previous trabeculectomy, cataract extraction with intraocular lens implantation, or both and uncontrolled glaucoma with intraocular pressure (IOP) > or =18 mm Hg and < or =40 mm Hg on maximum tolerated medical therapy.\nA 350-mm(2) Baerveldt glaucoma implant or trabeculectomy with mitomycin C (MMC 0.4 mg/ml for 4 minutes).\nIOP, visual acuity, use of supplemental medical therapy, surgical complications, and failure (IOP >21 mm Hg or not reduced by 20%, IOP < or =5 mm Hg, reoperation for glaucoma, or loss of light perception vision).", "label": []}
{"text": "Randomized, controlled, investigator-masked, single-site, parallel-group clinical trial.\nOne hundred twenty eyes of 120 patients with open-angle glaucoma or ocular hypertension who had inadequate IOP control after at least 6 weeks of monotherapy with a once-daily PGA (bimatoprost, latanoprost, or travoprost).\nStudy eyes were assigned randomly to adjunctive treatment with thrice-daily brimonidine tartrate 0.15% (n = 41), dorzolamide hydrochloride 2% (n = 40), or brinzolamide 1% (n = 39) for 4 months.\nEfficacy was evaluated by IOP measured at 10 am and 4 pm at baseline, month 1, and month 4.", "label": []}
{"text": "Subjects in these subsample groups have reported complaints of glare and wanted to administer eye drops to get quick eye relief and quality of vision for their daily activities including driving and computer works.\nFollowing 9 months of treatment with NAC lubricant eye drops, most patients' glare scores were improved or returned to normal in disability glare tests with Halometer DG.\nImprovement in disability glare was accompanied with independent improvement in acuity.\nFurthermore, patients with the poorest pretreatment vision were as likely to regain certain better visual function after 9 months of treatment with N-acetylcarnosine lubricant eye drops as those with the worth pretreatment vision.\nThe authors made a reference to electronic records of the product sales to patients who have been made the repurchase of the Can-C eye drops since December 2001.\nBased on this analysis of recorded adjustments to inventory, various parameters were analyzed during the continued repurchase behavior program, including testimonials from buyers.\nWith these figures, researchers judged on the patients' compliance rate to self-administer NAC eye-drops.", "label": []}
{"text": "Prospective randomized clinical trial.\nFifty-one medically uncontrolled CACG eyes with coexisting cataract of 51 patients.\nRecruited patients were randomized into group 1 (phacoemulsification alone) or group 2 (combined phacotrabeculectomy with adjunctive mitomycin C).\nPostoperatively, patients were reviewed every 3 months for 2 years.\nIntraocular pressure (IOP) and requirement for topical glaucoma drugs.", "label": []}
{"text": "Randomized, controlled clinical trial.\nFour hundred one infants in whom prethreshold ROP developed in one or both eyes and who were randomized after they were determined to have a high risk (> or =15%) of poor structural outcome without treatment using the Risk Management of Retinopathy of Prematurity (RM-ROP2) program.\nRefractive error was measured by cycloplegic retinoscopy.\nEyes with additional retinal, glaucoma, or cataract surgery were excluded.\nEyes were randomized to receive laser photocoagulation at high-risk prethreshold ROP (early treated [ET]) or to be conventionally managed (CM), receiving treatment only if threshold ROP developed.\nAstigmatism and high astigmatism at each visit.\nAstigmatism was classified as with-the-rule (WTR; 75 degrees -105 degrees ), against-the-rule (ATR; 0 degrees -15 degrees and 165 degrees -180 degrees ), or oblique (OBL; 16 degrees -74 degrees and 106 degrees -164 degrees ).", "label": []}
{"text": "Randomized clinical trial.\nSeventy-two medically controlled CACG eyes with coexisting cataract.\nRecruited patients were randomized into group 1 (phacoemulsification alone) or group 2 (combined phacotrabeculectomy with adjunctive mitomycin C).\nPostoperatively, patients were reviewed every 3 months for 2 years.\nIntraocular pressure (IOP) and requirement for topical glaucoma drugs.", "label": []}
{"text": "A randomized, placebo-controlled, double-masked, single-center trial.\nPatients with OAG who were younger than 65 years and had untreated IOP consistently of 16 mmHg or less.\nOral nilvadipine (2 mg twice daily) or placebo was assigned randomly to patients fulfilling the criteria by the minimization method of balancing the groups according to age, refraction, and the mean deviation (MD) value (Humphrey Perimeter 30-2 SITA Standard Program; Humphrey Instruments, Inc., San Leandro, CA) of the eye with less negative MD.\nNo topical ocular hypotensive drugs were prescribed.\nVisual field testing was performed every 3 months; fundus examination and IOP, blood pressure, and pulse rate measurements were carried out every month; and quantitative indexes of circulation in the optic disc rim (NB(ONH)) and choroid in the foveal area (NB(fovea)) were determined using the laser speckle method at 0, 3, 6, 12, 18, 24, 30, and 36 months.\nThe time courses of MD, NB(ONH), and NB(fovea) in the eye with less negative MD.", "label": []}
{"text": "Randomised controlled trial.\nCommunity in Sydney, Australia.\n616 men and women aged 70 years and over (mean age 81 years) recruited mainly from people attending outpatient aged care services.\nNo vision assessment or intervention\nComprehensive vision and eye examinations conducted by an optometrist.\nThree hundred subjects were seen by the study optometrist, with 146 judged to need treatment for a vision or eye problem.\nThe optometrist arranged new glasses for 92 subjects; 24 were referred for a home visit by an occupational therapist; 17 were referred for glaucoma management; and 15 were referred for cataract surgery.\nDistance and near visual acuity (logMAR) and composite scores on the 25-item version of the National Eye Institute Visual Function Questionnaire, both assessed at a 12-month follow-up home visit.", "label": []}
{"text": "Two phase III, multicenter, randomized, double-masked, parallel, placebo-controlled, clinical trials were conducted under a common protocol.\nThese data were pooled for analysis.\nThe setting for this study was a series of multicentered, private, and university-affiliated ophthalmology clinics in the United States.\nA total of 527 subjects were sequentially assigned, according to a computer-generated randomization list (2:1) to either bromfenac (n = 356) or placebo (n = 171).\nPotential subjects were excluded if using nonsteroidal anti-inflammatory drugs (NSAIDs), steroids, anticoagulants, or with uncontrolled ocular or systemic disease, preexisting ocular inflammation, surgical complications, or liver chemistry values of > or =Grade 1 according to World Health Organization Common Toxicity Criteria scoring.\nSubjects who underwent cataract surgery without prior anti-inflammatory treatment and had a postsurgical Summed Ocular Inflammation Score (SOIS) of > or =3 were treated with either bromfenac or placebo.\nSubjects self-instilled 1 drop of the assigned test agent twice-daily for 14 days and were followed for an additional 14 days for safety evaluation.\nSafety data were collected and the results for systemic safety are reported in this paper.", "label": []}
{"text": "Randomized, double-masked, multicenter, placebo-controlled trial.\nIndividuals with a diagnosis of POAG, CACG, pseudoexfoliative glaucoma (PEXG), or pigmentary glaucoma (PG), with a recorded intraocular pressure (IOP) of more than 21 mmHg, visual field or optic disc changes characteristic of glaucoma, and taking the maximum tolerated dose of medication.\nPatients received unilateral trabeculectomy with either 4 subconjunctival injections of CAT-152 (100 microg in 100 microl phosphate buffer) or 4 placebo injections, administered immediately before and on completion of trabeculectomy, and on the first day and at 1 week after surgery.\nPatients were followed up for 12 months after surgery.\nThe primary outcome measure was treatment success in the study eye (unmedicated IOP of 6-16 mmHg inclusive), at the 6- and 12-month follow-up.\nSecondary outcome measures were the incidence of postoperative intervention with 5-fluorouracil (5-FU); incidence of surgical failure; time to surgical failure; and incidence of vascularity, microcysts, and encapsulation or demarcation of the bleb site.", "label": []}
{"text": "Cross-sectional observational study.\nSubjects over the age of 50 years diagnosed as PACSs.\nSubjects were randomized to undergo laser peripheral iridotomy (LPI) in one eye.\nUltrasound biomicroscopy was performed before and a week after LPI.\nUltrasound biomicroscopy images were qualitatively assessed using standardized criteria.\nPlateau iris was defined in a quadrant by the presence of an anteriorly directed ciliary body, an absent ciliary sulcus, a steep iris root from its point of insertion followed by a downward angulation from the corneoscleral wall, presence of a central flat iris plane, and irido-angle contact.\nAt least 2 quadrants had to fulfil the above criteria for an eye to be defined as plateau iris.", "label": []}
{"text": "Prospective randomized 1-year trial.\nForty consecutive patients (40 eyes) with primary open-angle glaucoma and cataract.\nEyes were assigned randomly either to trabeculectomy with mitomycin C or to viscocanalostomy in combination with phacoemulsification and intraocular lens implantation.\nSuccess rate based on IOP.", "label": []}
{"text": "Randomized, controlled trial.\nCommunity in Sydney, Australia.\nSix hundred sixteen men and women aged 70 and older (mean age 81) recruited mainly from people attending outpatient aged care services.\nThe intervention group received comprehensive vision and eye examinations conducted by a study optometrist.\nThe optometrist arranged for new eyeglasses for 92 subjects and referred 24 for a home visit with an occupational therapist, 17 for glaucoma management, and 15 for cataract surgery.\nThe control group received usual care.\nFalls and fractures during 12 months of follow-up were ascertained according to self-report using a monthly postcard system.", "label": []}
{"text": "Randomized, multicenter, controlled clinical trial.\nLow-pressure glaucoma (LPG) patients 30 years or older were identified.\nExclusion criteria included an untreated pressure > 21 mmHg, advanced VF loss, and contraindications to study medications.\nA baseline VF was created using the average of 2 reliable Humphrey full-threshold examinations.\nA baseline diurnal IOP curve was performed without IOP-lowering medication.\nMean diurnal, peak, trough, IOP range (peak - trough), and standard deviation (SD) of IOP measurements, and mean deviation (MD) and corrected pattern SD (CPSD) of VF examinations.", "label": []}
{"text": "Randomized, double-masked, controlled, observational clinical trial.\nEight hundred fifty-four of 1077 ocular hypertensive participants within the EGPS were investigated.\nFour hundred twenty-nine patients were treated with dorzolamide and 425 patients received placebo.\nTreatment with dorzolamide or placebo (the vehicle of dorzolamide) in 1 or both eyes.\nCentral corneal thickness as measured by ultrasound pachymetry (DGH-500 Pachette; DGH Technologies, Exton, PA).\nThe CCT measurements were obtained in the morning before measuring IOP.\nFive measurements were taken from each eye of each patient within 5 minutes of application of anesthetic eye drops.", "label": []}
{"text": "Multicenter randomized clinical trial.\n17 Clinical Centers.\nPatients 18 to 85 years of age who had previous trabeculectomy and/or cataract extraction with intraocular lens implantation and uncontrolled glaucoma with intraocular pressure (IOP) > or =18 mm Hg and < or =40 mm Hg on maximum tolerated medical therapy.\n350 mm(2) Baerveldt glaucoma implant or trabeculectomy with mitomycin C (MMC).\nIOP, visual acuity, and reoperation for glaucoma.", "label": []}
{"text": "Randomized, double-masked, controlled clinical trial.\nOne thousand seventy-seven patients, > or =30 years old, were enrolled at 18 European centers.\nThe patients met inclusion criteria: intraocular pressure, 22 to 29 mmHg; 2 normal and reliable visual fields (VFs) (on the basis of mean deviation and corrected pattern standard deviation [PSD]); and a normal optic disc, as determined by an optic disc reading center.\nTreatment with dorzolamide or a placebo (the vehicle of dorzolamide) in one or both eyes.\nEfficacy end points were VF and/or optic disc changes.\nBaseline demographic and clinical data were collected before randomization, except for corneal thickness measurements, which were determined during follow-up.\nProportional hazards models were used to identify factors that predicted which participants in the EGPS had developed OAG.", "label": []}
{"text": "Multicenter randomized clinical trial.\nSeventeen clinical centers.\nTwo hundred twelve patients aged 18 to 85 years who had undergone previous trabeculectomy and/or cataract extraction with intraocular lens implantation and uncontrolled glaucoma with intraocular pressure > or =18 mm Hg and < or =40 mm Hg on maximum tolerated medical therapy.\nA 350-mm(2) Baerveldt glaucoma implant or trabeculectomy with mitomycin C (MMC).\nSurgical complications, reoperation for complications, visual acuity, and cataract progression.", "label": []}
{"text": "Double blind, randomised controlled trial.\nThree public hospitals in South Africa.\n450 black Africans with primary glaucoma.\nTrabeculectomy with 1000 cGy beta radiation or standard trabeculectomy without beta radiation (placebo).\nPrimary outcome measure was surgical failure within 12 months (intraocular pressure > 21 mm Hg while receiving no treatment for ocular hypotension).\nSecondary outcomes were visual acuity, surgical reintervention for cataract, and intraoperative and postoperative complications.", "label": []}
{"text": "Prospective, double-masked, placebo-controlled, randomized clinical trial.\nSixty-nine eyes of 43 patients were entered into the study, with 34 eyes randomized to receive active treatment and 35 placebo.\nTwo-year data were available for 60 of 69 (87%) eyes of 35 of 41 (85%) patients; 9 eyes of 6 patients were lost to follow-up, of which 6 received a placebo and 3 received intravitreal TA.\nTriamcinolone acetonide (0.1 ml) was injected through the pars plana using a 27-gauge needle.\nEyes randomized to placebo received a subconjunctival injection of saline.\nImprovement of best-corrected logarithm of the minimum angle of resolution visual acuity (VA) by > or =5 letters after 2 years and incidence of moderate or severe adverse events.", "label": []}
{"text": "Nonpenetrating deep sclerectomy was performed on all patients.\nPatients were randomly assigned to receive either a PMMA implant or a collagen implant.\nThe trial involved 60 patients (60 eyes) with medically uncontrolled primary and secondary open-angle glaucoma who were randomized to receive either a PMMA implant (30 eyes) or the collagen implant (30 eyes).\nThe patients were examined before and after the operation 1 day before surgery and at day 1; weeks 1, 2 and 3; and months 1, 2, 3, 6, 9, 12, 18, 24, and 30.\nAt each visit, the following examinations were performed: slit lamp examination, tonometry, visual acuity, and fundoscopy.", "label": []}
{"text": "Randomized controlled clinical trial.\nFifty-five patients scheduled for glaucoma surgery.\nPatients underwent routine trabeculectomy, with or without phacoemulsification and intraocular lens implantation.\nIn the study group (n = 28), sodium hyaluronate 2.3% was injected between the scleral and conjunctival flaps at the conclusion of the surgery.\nIn the control group (n = 27), balanced salt solution (BSS) was injected in the same fashion, in an unmasked design.\nSurgical success was defined as (1) a complete success if the intraocular pressure (IOP) was 21 mmHg or less without any antiglaucoma medication, and (2) a qualified success if the IOP was 21 mmHg or less, with or without antiglaucoma medication.\nPatients requiring additional surgery, including needling, or with IOP more than 21 mmHg, even when receiving antiglaucoma medications, were considered to have failed treatment.\nSuccess rates in both groups were compared using Kaplan-Meier survival curves and the log-rank test.\nThe morphologic characteristics of the filtering blebs were evaluated using the Indiana Bleb Appearance Grading Scale.\nOther outcome measures were IOP, visual acuity, need for antiglaucoma medication, and any complications.", "label": []}
{"text": "Multicenter randomized clinical trial.\n17 Clinical Centers.\nPatients 18 to 85 years of age who have undergone previous trabeculectomy, cataract extraction with intraocular lens implantation, or both and have inadequately controlled glaucoma with intraocular pressure (IOP) >or=18 mm Hg and <or=40 mm Hg on tolerated medical therapy.\nStudy patients were randomized to undergo placement of a 350-mm(2) Baerveldt glaucoma implant or trabeculectomy with mitomycin C (0.4 mg/ml for 4 minutes).\nIOP, complication rates, visual acuity, visual field, quality of life, reoperations for glaucoma, and need for supplemental medical therapy.", "label": []}
{"text": "Randomized, multicenter, double-masked clinical trial.\nLow-pressure glaucoma patients 30 years of age or older were identified.\nExclusion criteria included an untreated pressure of more than 21 mmHg, advanced visual field loss, and contraindications to study medications.\nRandomization of both eyes to double-masked monotherapy with brimonidine or timolol.\nFollow-up visits included Humphrey 24-2 full-threshold perimetry, tonometry every 4 months, and annual optic disc photography.\nProgression of visual field loss.", "label": []}
{"text": "Randomized, double-masked, controlled clinical trial.\nOne thousand eighty-one patients (age, > or =30 years) were enrolled by 18 European centers.\nThe patients fulfilled a series of inclusion criteria, including: IOP 22 to 29 mmHg; 2 normal and reliable visual fields (on the basis of mean deviation and corrected pattern standard deviation or corrected loss variance of standard 30/II Humphrey or Octopus perimetry); normal optic disc as determined by the Optic Disc Reading Center.\nPatients were randomized to treatment with dorzolamide or placebo (the vehicle of dorzolamide).\nEfficacy end points were visual field, optic disc changes, or both.\nA visual field change during follow-up had to be confirmed by 2 further positive tests.\nOptic disc change was defined on the basis of the agreement of 2 of 3 independent observers evaluating optic disc stereo slides.\nThe safety end point was an IOP of more than 35 mmHg on 2 consecutive examinations.", "label": []}
{"text": "Double-masked, prospective, randomized, placebo-controlled clinical trial.\nThree tertiary-referral teaching hospital vitreoretinal surgical units.\nOne hundred fifty-seven patients with established PVR (grade C, anterior or posterior) undergoing vitrectomy surgery.\nAll patients underwent vitreoretinal surgery and silicone oil exchange with or without membrane peeling and/or retinectomy.\nPatients were randomly allocated to perioperative infusion with or without 5-fluorouracil (200 microg/ml) and LMWH (5 IU/ml) in Hartmann's solution for 1 hour.\nThe primary outcome measure was defined as posterior retinal reattachment after removal of silicone oil without any reoperations at 6 months.\nSecondary outcome measures recorded were posterior retinal reattachment, localized/tractional retinal detachment, visual acuity, macular pucker, hypotony, glaucoma, keratopathy, and cataract.\nRemoval of silicone oil and reoperations were also recorded.", "label": []}
{"text": "Randomized controlled trial.\nPseudophakic patients with glaucoma requiring Nd:YAG posterior capsulotomy (n = 76).\nPatients undergoing Nd:YAG posterior capsulotomy were randomly allocated to receive no therapy, oral acetazolamide (250 mg), or topical apraclonidine 1% within 1 hour before capsulotomy.\nIntraocular pressures 1 and 3 hours after laser therapy were recorded.", "label": []}
{"text": "Randomized controlled clinical trial.\nSixty patients with refractory glaucoma.\nSixty eyes of 60 patients with refractory glaucoma were randomized to receive intraoperative MMC (0.5 mg/ml for 5 minutes) (n = 34) or balanced salt solution (n = 26) during Ahmed Glaucoma Valve implantation.\nSurgical success was defined according to 2 different criteria: (1) postoperative intraocular pressure (IOP) between 6 and 21 mmHg, with or without antiglaucoma medications, and (2) IOP reduction of at least 30% relative to preoperative values.\nEyes requiring additional glaucoma surgery, developing phthisis, or showing loss of light perception were classified as failures.\nSuccess rates in both groups were compared using Kaplan-Meier survival curves and the log rank test.\nOther outcome measures were mean IOP, number of glaucoma medications, and complications.", "label": []}
{"text": "This was a randomized, multicenter, investigator-masked, prospective, parallel-group, clinical trial.\nPatients with open-angle glaucoma or ocular hypertension.\nAfter washout of any previous ocular hypotensive medications, patients were randomly assigned to treatment with bimatoprost 0.03% ophthalmic solution QD (n=38) or latanoprost 0.005% ophthalmic solution QD (n=38) between 7 and 9 pm, or timolol maleate 0.5% gel-forming ophthalmic solution QD (n=39) between 7 and 9 am for 1 month.\nThe primary outcome measure, circadian IOP, was measured at eight time points over the course of 24 hours beginning at 8 am on day 28 and with the last measurement at 8 am on day 29.\nIOP was also measured at 8 am and 10 am at baseline and at 8 am on day 14.\nSafety measures included adverse events, biomicroscopy, visual acuity, heart rate, and blood pressure.", "label": []}
{"text": "A single-masked, two-center, crossover comparison with two 6-week treatment periods occurring after at least a 3-week medicine-free period.\nDiurnal curve intraocular pressures were taken at 2:00 AM, 6:00 AM, 10:00 AM, 2:00 PM, 6:00 PM, and 10:00 PM.\nThirty-four subjects with primary open-angle glaucoma or ocular hypertension were enrolled.\nLatanoprost 0.005% given every evening and TDFC twice daily.\nThe primary efficacy variable was diurnal intraocular pressure.", "label": []}
{"text": "Single-masked, parallel-group, prospective, randomized 24-month trial, with 90% power to detect a clinically important difference between groups.\nFifty consecutive patients (50 eyes) with primary open-angle or pseudoexfoliative glaucoma.\nEyes were assigned randomly to either viscocanalostomy (group 1) or trabeculectomy (group 2) with no intraoperative antifibrotics in the study eye.\nIn group 1, no further intervention was allowed, whereas trabeculectomy eyes could receive subconjunctival 5-fluorouracil (5-FU) injections or laser suture lysis after surgery.\nSuccess rate based on intraocular pressure (IOP), visual acuity, discomfort, and other complications.", "label": []}
{"text": "Randomized, multicenter, observer-masked, parallel-group study.\nTwo hundred ninety-three patients with ocular hypertension or primary open-angle glaucoma participated.\nAfter an open-label 3-week 0.5% timolol run-in period, patients with an hour 2 intraocular pressure (IOP) of > or = 22 mmHg were randomly assigned to receive either the dorzolamide/timolol combination twice daily or the concomitant use of brimonidine twice daily and timolol twice daily (brimonidine + timolol) for 6 months.\nThe IOP-lowering effects at hour 0 and hour 2 were collected at 1, 3, and 6 months.\nWe hypothesized that both treatment regimens would have comparable hour 2 IOP-lowering effects at month 3.\nThe treatments were considered comparable if the two-sided 95% confidence interval of the treatment difference was within +/- 1.5 mmHg.\nTolerability data were also collected at 1, 3, and 6 months.", "label": []}
{"text": "Prospective, randomized, placebo-controlled, double-masked cross-over trial.\nTwenty-seven patients with bilateral visual field damage resulting from NTG.\nPatients received 40 mg GBE, administered orally, three times daily for 4 weeks, followed by a wash-out period of 8 weeks, then 4 weeks of placebo treatment (identical capsules filled with 40 mg fructose).\nOther patients underwent the same regimen, but took the placebo first and the GBE last.\nVisual field tests, performed at baseline and at the end of each phase of the study, were evaluated for changes.\nChange in visual field and any ocular or systemic complications.", "label": []}
{"text": "A randomized, open-label, crossover study.\nTwenty-eight NTG patients with progressive visual field defects/optic disc excavation, new disc hemorrhage, or field defects that threatened fixation.\nPatients were randomly allocated to one of two groups.\nPatients in group 1 were treated with latanoprost, lubricant, and brimonidine for 4 weeks each, whereas patients in group 2 were treated with brimonidine, lubricant, and latanoprost for 4 weeks each.\nIntraocular pressure (IOP), pulse rate, and blood pressure were measured at 8 am, 12 noon, and 4 pm after each 4-week treatment.\nOcular perfusion pressure (OPP) was calculated.", "label": []}
{"text": "Randomized clinical trial.\nTwo hundred fifty-five patients aged 50 to 80 years (median, 68 years) with early glaucoma, visual field defects (median mean deviation, -4 dB), and a median IOP of 20 mm Hg, mainly identified through a population screening.\nPatients with an IOP greater than 30 mm Hg or advanced visual field loss were ineligible.\nPatients were randomized to either laser trabeculoplasty plus topical betaxolol hydrochloride (n = 129) or no initial treatment (n = 126).\nStudy visits included Humphrey Full Threshold 30-2 visual field tests and tonometry every 3 months, and optic disc photography every 6 months.\nDecisions regarding treatment were made jointly with the patient when progression occurred and thereafter.\nGlaucoma progression was defined by specific visual field and optic disc outcomes.\nCriteria for perimetric progression were computer based and defined as the same 3 or more test point locations showing significant deterioration from baseline in glaucoma change probability maps from 3 consecutive tests.\nOptic disc progression was determined by masked graders using flicker chronoscopy plus side-by-side photogradings.", "label": []}
{"text": "Randomized, double-blinded, controlled clinical trial.\nPatients (age > or =30 years) were enrolled from 18 European centers.\nThe patients fulfilled a series of inclusion criteria including the measurements of IOP (22-29 mmHg), two normal and reliable visual fields (VFs) (on the basis of mean defect and corrected pattern standard deviation/corrected loss of variance of standard 30/II Humphrey or Octopus perimetry), and normal optic disc as determined by the Optic Disc Reading Center (vertical and horizontal cup-to-disc ratios; asymmetry between the two eyes < or =0.4).\nPatients were randomized to the treatment with dorzolamide or a placebo.\nEnd points are VF and/or optic disc changes.\nA VF change during the follow-up must be confirmed by two further positive tests.\nOptic disc change is defined by the agreement of two out of three independent observers evaluating optic disc stereo-slides.", "label": []}
{"text": "Prospective, randomized, controlled trial.\nSeventy-three eyes of 64 consecutive patients with their first presentation of acute PACG, with intraocular pressure (IOP) levels of 40 mmHg or more, were recruited into the study.\nThe acute PACG eye of each consenting patient received topical pilocarpine (4%) and topical timolol (0.5%).\nThe patients were then randomized into one of two treatment groups.\nThe ALPI group received immediate ALPI under topical anesthesia.\nThe medical treatment group was given 500 mg of intravenous acetazolamide, followed by oral acetazolamide 250 mg four times daily, and an oral potassium supplement until IOP levels normalized.\nIntravenous mannitol also was administered to the latter group if the presenting IOP was higher than 60 mmHg.\nThe acute PACG eye of both groups continued to receive topical pilocarpine (1%) until peripheral iridotomy could be performed.\nIntraocular pressure profile, corneal clarity, symptoms, visual acuity, angle status by indentation gonioscopy, and complications of treatment.", "label": []}
{"text": "Randomized clinical trial.\nFifty consecutive patients scheduled for glaucoma surgery in one large surgical center.\nPatients underwent routine trabeculectomy.\nIn group 1, mitomycin-C (0.05 mg/ml) was applied topically to the filtering bleb on days 1, 2, and 3 after surgery (postoperative application).\nIn group 2, mitomycin-C (0.2 mg/ml) was applied by means of to a sponge during surgery (intraoperative application).\nPreoperative and postoperative intraocular pressure (IOP) values, visual acuity, the need for antiglaucoma medication, previous surgical procedures, and the need for further surgical interventions were monitored.", "label": []}
{"text": "Randomized controlled clinical trial.\nSix hundred seven newly diagnosed patients with open-angle glaucoma from 14 clinical centers.\nPatients were randomly assigned to either initial medical therapy or initial trabeculectomy.\nAfter treatment initiation and early follow-up, patients received clinical and QOL evaluations at 6-month intervals.\nQOL assessments were administered by telephone at a centralized interviewing center.\nThe CIGTS collected comprehensive QOL information that included both generic and vision-specific QOL measures.\nThis article focuses on initial treatment group differences related to symptom reporting, as measured by a Symptom and Health Problem Checklist, and changes in daily visual functioning, as measured by the Visual Activities Questionnaire (VAQ).", "label": []}
{"text": "Cross-sectional study.\nOne thousand three hundred one OHTS subjects with central corneal thickness measurements.\nCentral corneal thickness was determined with ultrasonic pachymeters of the same make and model at all clinical sites of the OHTS.\nCorrelation of mean central corneal thickness with race, baseline IOP, refraction, age, gender, systemic hypertension, and diabetes.", "label": []}
{"text": "Double-masked, randomized clinical trial.\nSixty-six patients underwent either laser peripheral iridotomy, argon laser trabeculoplasty, or neodymium:yttrium-aluminum-garnet laser capsulotomy.\nEyes received either one drop of brimonidine 0.2% or apraclonidine 0.5% before laser surgery.\nIntraocular pressure, heart rate, and blood pressure were measured before laser surgery and at 1 hour, 3 hours, 24 hours, and 1 week after laser surgery.", "label": []}
{"text": "Multicenter, 3-month, randomized, double-masked, interventional comparison trial.\nPatients diagnosed with ocular hypertension or glaucoma (n = 596).\nPatients received bimatoprost 0.03% ophthalmic solution once daily (8 PM, with vehicle control at 8 AM), bimatoprost 0.03% twice daily (8 AM; 8 PM), or timolol 0.5% twice daily (8 AM; 8 PM) in an uneven 2:2:1 randomization.\nScheduled visits were at prestudy, baseline (day 0), weeks 2 and 6, and month 3.\nIntraocular pressure (IOP) was measured at 8 AM (predose), 10 AM, and 4 PM.\nThe primary outcome measure was reduction in IOP in the eye with higher IOP at baseline.\nSecondary outcome measures included safety variables (adverse events, ophthalmoscopy, biomicroscopy, iris pigmentation, laser-flare meter, visual acuity, visual fields, heart rate, blood pressure, blood chemistry, hematology, and urinalysis).", "label": []}
{"text": "Baseline results from a randomized, controlled clinical trial.\nSix hundred seven patients from 14 clinical centers were enrolled.\nPatients randomized to initial medication received a stepped medical regimen (n = 307).\nThose randomized to initial surgery underwent a trabeculectomy (n = 300).\nThe baseline interview was conducted before treatment initiation.\nAll baseline and posttreatment QOL assessments were conducted by telephone from a centralized interviewing center.\nThe primary outcome measure described in this paper was QOL.\nThe QOL instrument is multidimensional and incorporates both disease-specific and generic measures, including the Visual Activities Questionnaire, Sickness Impact Profile, and a Symptom and Health Problem CHECKLIST:", "label": []}
{"text": "Double-masked, randomized, prospective, multicenter clinical trial.\nThree hundred sixty-nine subjects with bilateral ocular hypertension or open-angle glaucoma who had a baseline central corneal endothelial cell density of at least 1500 cells/mm(2), central corneal thickness of less than 0.68 mm, no corneal pathologic condition on slit-lamp examination, and intraocular pressure of less than 22 mmHg after a 3-week run-in on timolol, 0.5%, once daily were included.\nSubjects were randomly assigned to treatment with latanoprost 0.005% (n = 127), fixed-combination latanoprost 0.005%-timolol 0.5% (FC, n = 116), or timolol 0.5% (n = 126) one drop, once daily in the morning for 1 year.\nAll subjects were treated in both eyes.\nSpecular microscopy and ultrasonic pachymetry were performed before treatment, and after 6 and 12 months of treatment.\nMean percent change in central endothelial cell density and central corneal thickness after 1 year of treatment.", "label": []}
{"text": "An 8-week, double-masked, randomized, parallel-group, single-center clinical trial.\nA total of 108 patients with POAG or OH were enrolled.\nAfter completing a wash-out of ocular hypotensive medications, patients were randomized to receive either latanoprost once daily in the evening plus placebo once daily in the morning, or unoprostone twice daily (morning and evening).\nIOP was measured at 10:00 AM and at 5:00 PM at baseline and at week 8, and before 12:00 noon at week 2.\nOcular and systemic safety assessments were performed.", "label": []}
{"text": "Long-term follow-up on prior 1-year prospective, randomized study.\nA total of 200 eyes of 200 consecutive primary open-angle glaucoma patients who had undergone primary PT with capsular bag implantation of either a silicone IOL (102 eyes) or an acrylic IOL (98 eyes) according to the initial short-term prospective, randomized study protocol.\nThe study eyes underwent primary trabeculectomy, phacoemulsification, and posterior chamber IOL implantation.\nAdjunctive mitomycin C was used selectively, primarily in patients with one or more risk factors for filtration failure.\nIncidence of posterior capsular opacification (PCO), best-corrected visual acuity (BCVA), intraocular pressure (IOP), number of pressure-lowering medications, and filtration success rates, defined as maintenance of target IOP while on one (criteria 1) or zero (criteria 2) pressure-lowering medications without further surgical intervention.", "label": []}
{"text": "Prospective randomized trial.\nThirty-nine patients (78 eyes) with bilateral primary open angle glaucoma were included in the study.\nEyes were randomly assigned to receive deep sclerectomy in one eye and trabeculectomy in the other eye.\nMean intraocular pressure (IOP), postoperative medications, visual acuity, success rate, and complications.", "label": []}
{"text": "Prospective, randomized study.\nThe study consisted of 40 eyes of 40 patients with uncontrolled exfoliation glaucoma without a history of previous intra- or extraocular surgery and in need of cataract surgery.\nTemporal clear corneal phacoemulsification and foldable IOL implantation was performed in all eyes.\nIn the phaco-aspiration group, trabecular aspiration was performed with a suction force of 100-200 mmHg under light tissue-instrument contact using a modified intraocular aspiration probe.\nA modified Cairns-type trabeculectomy without adjunctive antimetabolites was performed superiorly in the phaco-trab eyes after IOL implantation.\nThe surgical outcome was assessed in terms of IOP change, need for adjunctive glaucoma medication, visual acuity outcome, and incidence of complications.", "label": []}
{"text": "Randomized, double-masked two-center clinical trial.\nThirty-two Asian patients with CACG, defined as glaucomatous optic neuropathy with a compatible visual field defect and at least 6 clock hours of synechial angle closure on gonioscopy were recruited.\nAll patients had previous peripheral iridotomy (PI) with IOP >21 mmHg after PI and were thereafter controlled (IOP <22 mmHg) with one or two pressure-reducing drugs.\nAfter a washout period, the patients were randomized to a 2-week treatment period with either placebo in the morning and 0.005% latanoprost in the evening or 0.5% timolol twice daily.\nThe short-term IOP reduction of latanoprost and timolol in patients with CACG.\nIOP was measured at baseline, and after 2, 7, and 14 days of treatment.\nIn addition, the short-term ocular and systemic adverse events of the two drugs were evaluated.", "label": []}
{"text": "A prospective, randomized study.\nSixty-eight patients (68 eyes) with refractory glaucomas were included in the study.\nEyes were randomly assigned to receive intraoperative mitomycin-C (0.3 mg/ml) applied under the conjunctival flap (group 1), scleral flap (group 2), or under both flaps (group 3).\nMean intraocular pressure (IOP), postoperative medications, visual acuity, filtering bleb appearance, and complications.", "label": []}
{"text": "Parallel, randomized, double-masked, and active-controlled study.\nEnrolled were 253 patients from 22 sites throughout the United States.\nAfter a 3-week run-in of timolol (TIMOPTIC; Merck & Co., Inc., Whitehouse Station, NJ) twice daily, eligible patients received either the combination (COSOPT; Merck & Co., Inc., Whitehouse Station, NJ) twice daily (plus placebo to ensure masking), timolol twice daily (plus placebo to ensure masking), or dorzolamide (TRUSOPT; Merck & Co. Inc., Whitehouse Station, NJ) three times daily for 3 months.\nIntraocular pressure taken at hours 0 (trough) and 2 (peak) after week 2 and months 1, 2, and 3 was compared to baseline within each treatment group and between the combination and each component group.\nThe safety profile of the combination was compared to each component.", "label": []}
{"text": "A 3-month, parallel, randomized, double-masked, active-controlled, multicenter clinical trial.\nA total of 335 patients with bilateral ocular hypertension or open-angle glaucoma participated.\nAfter completing a washout of ocular hypotensive medications, patients were randomized to receive either the dorzolamide-timolol combination twice daily plus placebo once daily, 0.5% timolol twice daily plus placebo once daily, or 2.0% dorzolamide three times daily.\nIntraocular pressure (IOP) was measured at morning trough (hour 0) and peak (2 hours postdose) on day 1, week 2, and months 1, 2, and 3.\nOcular and systemic safety were evaluated at each study visit.", "label": []}
{"text": "Randomized, clinical trial.\nNewly diagnosed patients 50 to 80 years of age with early glaucomatous visual field defects were mainly identified from a population-based screening of more than 44,000 residents of Malm\u00f6 and Helsingborg, Sweden.\nExclusion criteria were advanced visual field loss; mean IOP greater than 30 mmHg or any IOP greater than 35 mmHg; visual acuity less than 0.5; and inability to complete follow-up protocols.\nAfter informed consent, patients were randomized to treatment or no initial treatment with close follow-up.\nTreated patients had laser trabeculoplasty and started receiving topical betaxolol twice daily in eligible eyes.\nFollow-up visits include computerized perimetry and tonometry every 3 months and fundus photography every 6 months.\nDecisions to change or begin treatment are made jointly with the patient when EMGT progression occurs and also later if clinically needed.\nThe EMGT progression is defined by sustained increases of visual field loss in three consecutive C30-2 Humphrey tests, as determined from computer-based analyses, or by optic disc changes, as determined from flicker chronoscopy and side-by-side comparisons of fundus photographs performed by masked, independent graders.", "label": []}
{"text": "Prospective, controlled study randomized with respect to assignment to trabecular aspiration, with a case-control design between the asp+IOL and triple procedure groups.\nSeventy-four eyes of 74 patients with uncontrolled pseudoexfoliation glaucoma without a history of previous intraocular or extraocular surgery and in need of cataract surgery.\nForty-eight patients were randomized to those receiving adjunctive trabecular aspiration (asp+IOL group of 26 eyes) and those given no trabecular aspiration (IOL-alone group of 22 eyes).\nThe triple procedure group consisted of 26 cases, closely matched to the asp+IOL cases in terms of age, sex, cup-disc ratio, glaucoma medication requirements, and systemic diseases.\nTemporal clear corneal phacoemulsification and foldable IOL implantation was performed in all eyes.\nIn the asp+IOL group, trabecular aspiration was performed with a suction force of 100 to 200 mm Hg under light tissue-instrument contact using a modified intraocular aspiration probe.\nA modified Cairns-type trabeculectomy without adjunctive antimetabolites was performed superiorly in the triple procedure eyes after IOL implantation.\nSurgical outcome was assessed in terms of IOP change, need of adjunctive glaucoma medication, visual acuity outcome, and complications.\nSurgical failure was defined as an outcome requiring additional surgical intervention or more than 1 medication to achieve IOP control to the target pressure.", "label": []}
{"text": "Prospective, randomized, double-masked, clinical trial.\nA total of 56 eyes of 41 patients with open-angle glaucoma or ocular hypertension were entered in the study; 46 eyes of 41 patients were eventually used for the final analysis.\nPatients were randomized to receive either brimonidine 0.2% or apraclonidine 1.0% before and after 360 degrees ALT.\nBoth patient and physician were masked as to which agent each patient received.\nIntraocular pressure measurements were recorded before surgery and at 1, 2, and 4 hours after surgery.\nThe difference between the preoperative IOP (baseline) and the highest recorded postoperative IOP was recorded as the maximum IOP change.\nThe mean of the maximum IOP change for each group was analyzed using a two-sample, one-tailed t test.", "label": []}
{"text": "Retrospective, noncomparative, case series.\nNinety-six patients were identified from the authors' tertiary glaucoma practice who were treated with brimonidine.\nTheir glaucoma was uncontrolled despite maximal tolerated medical therapy before receiving brimonidine, and some had previously undergone argon laser trabeculoplasty or filtration surgery.\nThe patients were subdivided according to their glaucoma diagnosis: open-angle (OAG), angle-closure (ACG), mixed mechanism, and congenital glaucoma.\nBoth the short- (about 2 weeks) and long-term results were evaluated.\nTwenty-two patients were excluded because additional medication changes were made at the time of introduction of brimonidine.\nBrimonidine was added to the existing regimen of glaucoma medication.\nIntraocular pressure (IOP) was recorded at all follow-up dates, together with visual field examination and optic disc evaluation twice yearly.", "label": []}
{"text": "Prospective, randomized, clinical trial.\nThirty-two eyes of 32 patients with medically uncontrolled POAG.\nStandard limbus-based trabeculectomy with adjunct mitomycin C (0.3 mg/mL for 3 minutes) in 16 eyes of 16 patients; AIGT was performed in 16 eyes of 16 patients.\nThe groups were matched for age, preoperative IOP, duration of preoperative antiglaucoma treatment, use of preoperative beta-blockers and parasympathomimetics, and use of beta-blockers in the fellow eye.\nThe IOP (average of the two highest values measured in the diurnal curve, from 8 AM to 6 PM, every 2 hours) and complications were recorded 1, 3, 6, 12, 18, and 24 months after surgery.\nIdentification of complications and IOP.", "label": []}
{"text": "Prospective randomized clinical trial.\nTwo hundred twenty-eight eyes of 228 patients with primary open-angle glaucoma undergoing ALT were studied.\nPatients were given 1 drop of either apraclonidine 1% (n = 114) or pilocarpine 4% (n = 114) 15 minutes before ALT.\nPeri-ALT IOPs and incidences of post-ALT IOP spikes at 5 minutes, 1 hour, and 24 hours were compared between the two groups.", "label": []}
{"text": "Analysis of visual field decay during a prospective, randomized clinical trial comparing primary laser trabeculoplasty with medication.\nOf a total of 82 included eyes in 82 patients with newly detected high-pressure open-angle glaucomas, 76 (55 capsular, 21 simple) fulfilled the 2-year follow-up with the stated number of reliable visual field examinations and were included in this analysis.\nAutomated perimetry and a daytime IOP curve were taken every second month during the 2-year follow-up.\nSix IOP parameters were evaluated and correlated to visual field outcome.\nThe subgroups with the two types of glaucoma (capsular and simple) were analyzed separately.", "label": []}
{"text": "Randomized, controlled clinical trial.\nA total of 607 patients with open-angle glaucoma were enrolled.\nPatients randomized to initial medications (n=307) received a stepped regimen of medications to lower intraocular pressure.\nThose randomized to initial surgery (n=300) underwent trabeculectomy to lower intraocular pressure.\nProgression in visual field loss constitutes the study's primary outcome variable.\nSecondary outcomes include health-related quality of life, visual acuity, and intraocular pressure.", "label": []}
{"text": "Prospective, randomized, double-masked, clinical study.\nThirty-six patients affected with bilateral pigmentary glaucoma controlled with no more than a single hypotensive medication were enrolled in the study.\nThe sample population was randomly divided into 2 age- and gender-matched groups each of 18 patients.\nGroup 1 received 0.005% latanoprost eyedrops once daily and the vehicle (placebo) once daily; group 2 was assigned to timolol 0.5% eyedrops twice daily.\nDiurnal curves of intraocular pressure (IOP) were performed on the baseline day and after 0.5, 3, 6, and 12 months of treatment.\nThe IOP measurements were performed at 8:00 AM, 12:00 noon, 4:00 PM, and 8:00 PM.\nOutflow facility (\"C\") was measured on the baseline day and on the last day of the study with a Schiotz electronic tonometer.\nA two-tailed Student's t test for paired or unpaired data was used for statistical evaluation of differences between treatment and baseline values or between the latanoprost and timolol group.\nDiurnal IOP measurements were compared hour by hour.\nMean values of the two eyes IOP and \"C\" were used for analysis.", "label": []}
{"text": "Randomized, masked, and partially controlled trial.\nSixty eyes of 60 Asian patients undergoing extracapsular cataract extraction with intraocular lens implantation were examined.\nOf these, 28 eyes of 28 patients served as control eyes.\nPatients were stratified for age and presence of diabetes mellitus.\nSurodex was inserted in the anterior chamber of 32 eyes at the conclusion of surgery.\nThese eyes received placebo eyedrops four times a day after surgery for 4 weeks.\nControl eyes received neither Surodex nor a placebo implant but were prescribed conventional 0.1% dexamethasone eyedrops four times a day for 4 weeks.\nAnterior chamber cells and flare were clinically graded at the slit lamp.\nAnterior chamber flare was objectively assessed with the Kowa FM500 Laser Flare Meter (Kowa Co. Ltd, Tokyo, Japan) for up to 3 months after surgery.\nIntraocular pressure and corneal endothelial specular microscopy with morphometric cell analysis were performed for up to 1 year after surgery.", "label": []}
{"text": "Randomized, crossover, cross-sectional, clinical trial.\nTwo hundred unselected patients with definite or suspect glaucoma or neuro-ophthalmic VF indication participated.\nAll patients completed two 30-2 tests of one eye on a Humphrey perimeter, one with continuous active technician supervision and one without supervision after the initial 2 minutes of the test.\nVisual field reliability and global VF indices were measured.", "label": []}
{"text": "A prospective randomized study.\nA university-affiliated referral eye hospital.\nThirty consecutive patients requiring trabeculectomy for uncontrolled primary glaucoma.\nFifteen patients underwent trabeculectomy with permanent interrupted sutures; the same number underwent trabeculectomy with releasable sutures.\nIncidence of short-term shallowing of anterior chamber or hypotony and related complications, and long-term intraocular pressure control and bleb score.", "label": []}
{"text": "A double-masked, parallel-group, active-controlled, multicenter clinical trial of 12 months' duration.\nFour hundred eighty-three patients with glaucoma or ocular hypertension were enrolled.\nOf these, 463 were evaluated according to the protocol criteria (280 in the brimonidine tartrate group and 183 in the timolol group).\nBrimonidine tartrate 0.2% or timolol maleate 0.5% was administered twice daily.\nThe primary efficacy variable was intraocular pressure (IOP).", "label": []}
{"text": "Parallel, randomized, double-masked, and active-controlled study.\nEnrolled were 253 patients from 22 sites throughout the United States.\nAfter a 3-week run-in of timolol (TIMOPTIC; Merck & Co., Inc., Whitehouse Station, NJ) twice daily, eligible patients received either the combination (COSOPT; Merck & Co., Inc., Whitehouse Station, NJ) twice daily (plus placebo to ensure masking), timolol twice daily (plus placebo to ensure masking), or dorzolamide (TRUSOPT; Merck & Co. Inc., Whitehouse Station, NJ) three times daily for 3 months.\nIntraocular pressure taken at hours 0 (trough) and 2 (peak) after week 2 and months 1, 2, and 3 was compared to baseline within each treatment group and between the combination and each component group.\nThe safety profile of the combination was compared to each component.", "label": []}
{"text": "A 3-month, parallel, randomized, double-masked, active-controlled, multicenter clinical trial.\nA total of 335 patients with bilateral ocular hypertension or open-angle glaucoma participated.\nAfter completing a washout of ocular hypotensive medications, patients were randomized to receive either the dorzolamide-timolol combination twice daily plus placebo once daily, 0.5% timolol twice daily plus placebo once daily, or 2.0% dorzolamide three times daily.\nIntraocular pressure (IOP) was measured at morning trough (hour 0) and peak (2 hours postdose) on day 1, week 2, and months 1, 2, and 3.\nOcular and systemic safety were evaluated at each study visit.", "label": []}
{"text": "A prospective randomized study.\nOne hundred seventy-four eyes of 174 nonselected patients with primary open-angle glaucoma (POAG) were randomized to either no adjunctive mitomycin C (MMC) control group of 93 eyes of 93 patients) or adjunctive subconjunctival MMC (MMC group of 81 eyes of 81 patients) during the primary glaucoma triple procedure (PGTP).\nPrimary glaucoma triple procedure with and without MMC and YAG laser capsulotomy for posterior capsular opacification (PCO) was performed.\nThe incidences of YAG capsulotomy for PCO were compared between the control and MMC groups and also between the control group and the MMC subgroups (1 minute, 3 minutes, and 5 minutes of MMC application) using Kaplan-Meier analysis with Mantel-Cox log-rank test.\nCox proportional hazard regression analysis also was performed to identify significant factors affecting capsular opacification.", "label": []}
{"text": "A randomized controlled trial.\nA total of 332 black patients (451 eyes), 249 white patients (325 eyes), and 10 patients of other races (13 eyes) participated.\nPotential follow-up ranged from 4 to 7 years.\nEyes were randomly assigned to either an argon laser trabeculoplasty (ALT)-trabeculectomy-trabeculectomy (ATT) sequence or a trabeculectomy-ALT-trabeculectomy (TAT) sequence.\nThe second and third interventions were offered after failure of the first and second interventions, respectively.\nAverage percent of eyes with decrease of visual field (APDVF), average percent of eyes with decrease of visual acuity (APDVA), and average percent of eyes with decrease of vision (APDV) are the outcome measures.\nDecrease of visual field (DVF) is an increase from baseline of at least 4 points on a glaucoma visual field defect scale ranging from 0 to 20, decrease of visual acuity (DVA) is a decrease from baseline of at least 15 letters (3 lines), and decrease of vision (DV) is the occurrence of either DVF or DVA.\nThe averages are of percent decreases observed at 6-month intervals from the first 6-month visit to the end of the specified observation period.", "label": []}
{"text": "Multicenter, randomized, controlled trial.\nA total of 332 black patients (451 eyes), 249 white patients (325 eyes), and 10 patients of other races (13 eyes) with open-angle glaucoma that could not be controlled by medical therapy alone participated.\nThere was no intervention performed.\nThe investigators compare the baseline demographic, medical, and ophthalmic characteristics of black and white patients, adjusting the comparisons for age and gender.", "label": []}
{"text": "A prospective, controlled study that was randomized with respect to assignment to adjunctive MMC and a case-control design with respect to comparisons between SGTP and PGTP was studied.\nThe SGTP group consisted of 49 eyes of 49 consecutive patients with primary open-angle glaucoma with a history of glaucoma filtration surgery requiring glaucoma medical therapy and in need of cataract surgery, randomized to adjunctive MMC (SGTP MMC subgroup of 21 eyes) and no adjunctive MMC (SGTP control subgroup of 28 eyes).\nThe PGTP group consisted of 49 PGTP cases closely matched to the SGTP cases with respect to age, race, gender, MMC use, C:D ratio, and systemic diseases.\nTrabeculectomy combined with phacoemulsification and a small incision (5 x 6 mm), all polymethylmethacrylate posterior chamber intraocular lens implantation with or without adjunctive MMC (0.5 mg/ml for 1 minute), was performed.\nSurgery failure was defined as the need of an additional intraocular procedure or the need of more than one medication to achieve intraocular pressure control to the target level.\nIntragroup and intergroup comparisons were made with respect to filtration outcome among the SGTP and PGTP patients.", "label": []}
{"text": "This was a prospective, open-label, two-protocol clinical study.\nSixteen patients with ocular hypertension or with primary open-angle glaucoma were studied.\nBaseline AHF was measured by computerized fluorophotometry and IOP by pneumatonometry without antiglaucoma therapy.\nIn the first protocol, dorzolamide was randomized to one eye (N = 10) and IOP and AHF measurements were repeated.\nOne week later, having used dorzolamide in one eye three times daily, patients had measurements performed before and after the single administration of oral acetazolamide 250 mg.\nIn the second protocol, having used acetazolamide 250 mg four times daily for 4 to 7 days (N = 6), patients had measurements performed before and after a single drop of dorzolamide was instilled randomly into one eye.\nThe patient continued acetazolamide and unilateral dorzolamide for 4 to 7 more days and returned for IOP and AHF measurements.\nIntraocular pressure and AHF were measured in treated and contralateral control eyes.", "label": []}
{"text": "The study was designed as a randomized, 6-month double-masked parallel group, multicenter study comparing latanoprost with timolol followed by an 18-month open-label, multicenter study in which all patients were treated with latanoprost.\nIn total, 277 patients were treated with latanoprost for up to 24 months.\nFor the first 6 months of treatment, latanoprost (0.005%) administered once daily was compared with timolol (0.5%) administered twice daily.\nPatients then received latanoprost (once daily) for an 18-month follow-up period regardless of their initial treatment.\nIntraocular pressure (IOP) was measured over the 24-month treatment period, and any ocular-systemic symptoms or adverse events were evaluated.", "label": []}
{"text": "Prospective, randomized.\nA total of 79 eyes of 79 primary open-angle glaucoma (POAG) patients in need of combined surgery were randomized to a silicone IOL group (36 eyes) and acrylic IOL group (43 eyes).\nThe study eyes underwent PGTP, which consisted of primary trabeculectomy, phacoemulsification, and posterior chamber IOL implantation.\nAdjunctive mitomycin C (MMC) (0.5 mg/ml for 1 minute) was used selectively only in patients with one or more risk factors for filtration failure of PGTP.\nSnellen visual acuity, intraocular pressure (IOP), slit-lamp biomicroscopy, and number of glaucoma medications were measured, performed, or determined preoperatively and at regular intervals postoperatively.", "label": []}
{"text": "A short-term, randomized, placebo-controlled, double-masked study.\nTwenty-four patients with glaucoma with elevated IOPs.\nAcetazolamide 250 mg twice daily from day 1 to day 18.\nTopical 50 micrograms/ml latanoprost or placebo eye drops bilaterally instilled once daily from day 4 to day 18.\nIOP, conjunctival hyperemia.", "label": []}
{"text": "Participants were assigned randomly to one of two treatment groups.\nSeventy-four patients with cataract and without evidence of glaucoma were studied.\nPatients were randomized to receive either single- or two-quadrant conjunctival peritomy and phacoemulsification.\nTonometry and tonography were assessed before surgery and at 1 day, 1 week, 6 weeks, and 1 year after surgery by a masked observer.", "label": []}
{"text": "A randomized, prospective study.\nTwo hundred eighty-two eyes that underwent a guarded filtration procedure between January 1994 and January 1996 at the Glaucoma Service of University of Campinas.\nEncapsulated blebs developed in 25 (8.9%) of 282 eyes and were randomized to either needling (n = 14) or medical treatment with aqueous humor suppressants (n = 11).\nIf one treatment failed to maintain intraocular pressures (IOPs) below 20 mmHg, the other treatment was initiated.\nIf both methods failed, surgical revision or further glaucoma surgery was performed.\nComplete success was defined as IOP less than 20 mmHg after one treatment method.\nQualified success was defined when IOPs less than 20 mmHg were obtained with both treatment methods, whereas failure was defined when IOP greater than 20 mmHg or when further surgery was indicated.\nIntraocular pressure, vision, and number of antiglaucoma medications.", "label": []}
{"text": "Randomized, prospective study.\nTeaching hospital.\n40 unpremedicated outpatients with history of primary open angle glaucoma undergoing trabeculectomy.\nIn the operating room, an infusion of 5% dextrose into a peripheral vein was started.\nThe propofol group (n = 20) received 0.5 mg/kg i.v.\npropofol bolus followed immediately by a continuous 0.5 mg/kg/hr infusion.\nThe control group (n = 20) received only the dextrose solution.\nA peribulbar block was performed with bupivacaine with added adrenaline, plus lidocaine.\nThe ocular pressure (tonometer) on the eye undergoing trabeculectomy and the other eye, blood pressure (BP), and heart rate (HR) were measured at the following times: (1) preoperatively; (2) 2 minutes; (3) 5 minutes; (4) 10 minutes; (5) 15 minutes after propofol bolus administration for the propofol group (approximately 4 minutes after the peribulbar blockade on the eye undergoing surgery for the propofol and control groups).", "label": []}
{"text": "Prospective, randomized, multicentered surgical trial.\nCommunity- and university-based vitreoretinal practices.\nTwo-hundred sixty-five eyes with PVR randomized to perfluoropropane gas and silicone oil with follow-up through 3 years (cohort 1) and 249 eyes with attached maculas at 36 months (121 eyes randomized to long-acting gas [either sulfur hexafluoride or perfluoropropane] and 128 eyes randomized to silicone oil) with follow-up up to 6 years (cohort 2).\nBoth cohorts consisted of eyes that had and had not undergone vitrectomy for PVR (groups 1 and 2, respectively) before randomization.\nOf the 265 eyes in cohort 1, 24-month follow-up data were available for 218 eyes (82%) and 36-month follow-up data were available for 196 eyes (74%).\nOf 208 eyes in cohort 2, 48-month follow-up data were available for 146 eyes (70%), 60-month follow-up data for 119 eyes (57%), and 72-month follow-up data for 73 eyes (35%).\nVitrectomy surgery for PVR with a long-acting gas or silicone oil as the intraocular tamponade.\nChanges in visual acuity, recurrent retinal detachment, and incidence of complications.", "label": []}
{"text": "A double-masked, randomized, parallel comparison.\nMultinational study at 34 international sites.\nFive hundred twenty-three patients with open-angle glaucoma or ocular hypertension, 17 to 85 years of age.\nPatients currently using ocular hypotensive medications were required to undergo a washout.\nTwo percent dorzolamide three times a day, 0.5% timolol (Timoptic, Merck, Whitehouse Station, NJ) twice daily, and 0.5% betaxolol solution (Betoptic, Alcon, Fort Worth, Tex) twice daily.", "label": []}
{"text": "A prospective 90 day, multi-centered, placebo-controlled, doublemasked parallel study.\nWe enrolled 174 glaucoma patients with inadequate IOP control on maximally tolerated medical therapy.\nAll were candidates for either laser trabeculoplasty or invasive surgical intervention.\nWe enrolled only one eye per patient.\nWe continued to administer maximum-tolerated medical therapy for glaucoma.\nPatients took the study medication every eight hours.\nStudy medications were either apraclonidine hydrochloride 0.5% or placebo (apraclonidine's vehicle).\nWe evaluated IOP, IOP change from baseline, and the number of eyes requiring surgery after the addition of study medication.", "label": []}
{"text": "Prospective multicenter cohort study incorporating 2 natural history groups and 2 randomized controlled clinical trials.\nEight ophthalmic practices in the USA and 1 in France, primarily associated with academic centers.\nSeven hundred and twenty-five patients with CVO (728 eyes) divided into 4 study groups on the basis of the perfusion status of the retina and presence of decreased vision associated with macular edema: perfused, nonperfused, indeterminate, and macular edema.\nNonperfused group: random assignment to panretinal photocoagulation or watchful waiting.\nMacular edema group: random assignment to grid pattern photocoagulation or watchful waiting.\nNatural history groups: no intervention.\nDescription of population and eyes based upon clinical examination and central assessment of fundus angiography, iris photographs, and stereo color fundus photographs.", "label": []}
{"text": "Four-week, double-masked, randomized, placebo-controlled, parallel, three-center study.\nReferral centers.\nForty-eight patients with bilateral open angle glaucoma or ocular hypertension and intraocular pressure (IOP) greater than 22 mm Hg entered the study.\nTwo of 28 patients receiving dorzolamide and two of 20 patients receiving placebo were withdrawn due to adverse experiences.\nDorzolamide (2%) or placebo to each eye three times daily for 4 weeks.\nDiurnal IOP curves; ophthalmologic evaluations including corneal ultrasound pachymetry and endothelial cell count; and systemic evaluations including vital signs, blood chemistries, complete blood cell counts, urinalysis, electrocardiogram, and drug and carbonic anhydrase activity levels in red blood cells.", "label": []}
